Jundishapur Journal of Microbiology

Published by: Kowsar

Prevalence of Cytomegalovirus in Patients With Multiple Sclerosis: A Case-Control Study in Northern Iran

Saeideh Najafi 1 , * , Masood Ghane 1 , Vahdat Poortahmasebi 2 , Seyed Mohammad Jazayeri 2 and Shahrokh Yousefzadeh-Chabok 3
Authors Information
1 Department of Microbiology, Tonekabon Branch, Islamic Azad University, Tonekabon, Mazandaran, IR Iran
2 Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Neurosurgery, Guilan University of Medical Sciences, Rasht, Guilan, IR Iran
Article information
  • Jundishapur Journal of Microbiology: July 01, 2016, 9 (7); e36582
  • Published Online: July 3, 2016
  • Article Type: Research Article
  • Received: January 24, 2016
  • Revised: May 25, 2016
  • Accepted: June 18, 2016
  • DOI: 10.5812/jjm.36582

To Cite: Najafi S, Ghane M, Poortahmasebi V, Jazayeri S M, Yousefzadeh-Chabok S. Prevalence of Cytomegalovirus in Patients With Multiple Sclerosis: A Case-Control Study in Northern Iran, Jundishapur J Microbiol. 2016 ; 9(7):e36582. doi: 10.5812/jjm.36582.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician. 2004; 70(10): 1935-44[PubMed]
  • 2. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009; 15(7): 543-55[DOI][PubMed]
  • 3. Riccio P, Rossano R. Nutrition facts in multiple sclerosis. ASN Neuro. 2015; 7(1)[DOI][PubMed]
  • 4. Goldenberg MM. Multiple sclerosis review. P T. 2012; 37(3): 175-84[PubMed]
  • 5. Pender MP, Greer JM. Immunology of multiple sclerosis. Curr Allergy Asthma Rep. 2007; 7(4): 285-92[PubMed]
  • 6. Pawate S, Sriram S. The role of infections in the pathogenesis and course of multiple sclerosis. Ann Indian Acad Neurol. 2010; 13(2): 80-6[DOI][PubMed]
  • 7. Brooks GF, Carroll KC, Butel JS, Morse SA. Jawetz, Melnick, and Adelberg's medical microbiolog. 2013;
  • 8. Griffiths PD, Panjwani DD, Stirk PR, Ball MG, Ganczakowski M, Blacklock HA, et al. Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci. Lancet. 1984; 2(8414): 1242-5[PubMed]
  • 9. Halenius A, Hengel H. Human cytomegalovirus and autoimmune disease. Biomed Res Int. 2014; 2014: 472978[DOI][PubMed]
  • 10. Sanadgol N, Ramroodi N, Ahmadi GA, Komijani M, Moghtaderi A, Bouzari M, et al. Prevalence of cytomegalovirus infection and its role in total immunoglobulin pattern in Iranian patients with different subtypes of multiple sclerosis. New Microbiol. 2011; 34(3): 263-74[PubMed]
  • 11. Sundqvist E, Bergstrom T, Daialhosein H, Nystrom M, Sundstrom P, Hillert J, et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler. 2014; 20(2): 165-73[DOI][PubMed]
  • 12. Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology. 2011; 76(23): 1989-95[DOI][PubMed]
  • 13. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1): 121-7[PubMed]
  • 14. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6): 840-6[DOI][PubMed]
  • 15. Selgrade MK, Cooper GS, Germolec DR, Heindel JJ. Linking environmental agents and autoimmune disease: an agenda for future research. Environ Health Perspect. 1999; 107 Suppl 5: 811-3[PubMed]
  • 16. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996; 85(3): 299-302[PubMed]
  • 17. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001; 286(24): 3083-8[PubMed]
  • 18. Zivadinov R, Nasuelli D, Tommasi MA, Serafin M, Bratina A, Ukmar M, et al. Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. Neurol Res. 2006; 28(3): 262-9[DOI][PubMed]
  • 19. Sinclair J, Sissons P. Latent and persistent infections of monocytes and macrophages. Intervirology. 1996; 39(5-6): 293-301[PubMed]
  • 20. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol. 1991; 72 ( Pt 9): 2059-64[DOI][PubMed]
  • 21. Pirko I, Cardin R, Chen Y, Lohrey AK, Lindquist DM, Dunn RS, et al. CMV infection attenuates the disease course in a murine model of multiple sclerosis. PLoS One. 2012; 7(2)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments